Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
32,500
Bristol-Myers Squibb Co News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.20 | 4.30 | -0.05% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,669.88 | 165.21 | 0.36% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,996.34 | 117.16 | 0.54% |
| Nikkei 225 | 53,429.56 | 15.88 | 0.03% |
| NZX 50 Index | 13,069.66 | 167.51 | 1.30% |
| S&P 500 | 6,611.83 | 29.14 | 0.44% |
| S&P/ASX 200 | 8,728.80 | 1.50 | -0.02% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |